Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05043090 · ClinicalTrials.gov registry record · Phase 3

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

A Phase 3 study of Papillary Renal Cell Carcinoma, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
148
Enrollment target
20
Study locations

NCT05043090 is a Phase 3 study of Papillary Renal Cell Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 148 participants, below the 229-participant average among 8 other Papillary Renal Cell Carcinoma trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05043090, a Phase 3 study of Papillary Renal Cell Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
148 participants
Enrollment target
20
Study locations

Study Summary

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).

Conditions Studied

Papillary Renal Cell Carcinoma

Interventions

  • DRUG durvalumab
  • DRUG savolitinib
  • DRUG sunitinib

Study Locations (20)

Other

  • Research Site - Buenos Aires
  • Research Site - CABA
  • Research Site - Ciudad Autonoma Buenos Aires
  • Research Site - Ciudad Autónoma Buenos Aires
  • Research Site - Córdoba
  • Research Site - La Plata
  • Research Site - Rosario
  • Research Site - San Miguel de Tucumán
  • Research Site - Box Hill
  • Research Site - Macquarie University
  • Research Site - St Leonards
  • Research Site - Belo Horizonte
  • Research Site - Brasília
  • Research Site - Cachoeiro de Itapemirim
  • Research Site - Criciúma
  • Research Site - Curitiba
  • Research Site - Florianópolis
  • Research Site - Fortaleza

Massachusetts

  • Research Site - Boston

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2021-10-28
Est. Completion 2025-10-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05043090

The ClinicalTrials.gov registry entry for NCT05043090 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 8 other Papillary Renal Cell Carcinoma trials with a reported enrollment target (35% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Papillary Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which durvalumab is the first listed.

NCT05043090 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05043090 about?

NCT05043090 is a clinical study titled "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC". A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).

What is the current status of trial NCT05043090?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2021-10-28. Estimated completion is 2025-10-30.

What conditions does trial NCT05043090 study?

This clinical trial studies the following conditions: Papillary Renal Cell Carcinoma.

What interventions are being tested in trial NCT05043090?

The interventions under investigation include: durvalumab (DRUG), savolitinib (DRUG), sunitinib (DRUG).

Who is sponsoring clinical trial NCT05043090?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05043090 being conducted?

This trial has 20 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Papillary Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Papillary Renal Cell Carcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.